You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.

Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
12.17.12
Ironwood and Forest Announce U.S. Availability of LINZESS™ (Linaclotide)
12.06.12
Protagonist and Ironwood Expand Peptide Drug Discovery Collaboration
11.28.12
Constella® (linaclotide) Approved in Europe for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults
11.09.12
Ironwood Pharmaceuticals to Present at the Credit Suisse 2012 Healthcare Conference
11.01.12
Ironwood Pharmaceuticals to Host Webinar on Accounting Treatment for LINZESS™ (Linaclotide)
10.23.12
Ironwood and AstraZeneca Announce Linaclotide Collaboration for China
10.16.12
Ironwood Pharmaceuticals Provides Third Quarter 2012 Investor Update
10.09.12
Ironwood Pharmaceuticals to Host Third Quarter 2012 Investor Update Call
09.21.12
Linaclotide Receives Positive CHMP Opinion for the Treatment of IBS-C
09.12.12
Ironwood Pharmaceuticals to Present at the UBS Global Life Sciences Conference
09.06.12
Ironwood Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
08.30.12
Ironwood and Forest Announce FDA Approval of LINZESS™ (Linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation
08.30.12
Ironwood and Forest to Host Conference Call to Discuss FDA Approval of LINZESS™ (Linaclotide) for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation
07.17.12
Ironwood Pharmaceuticals Provides Second Quarter 2012 Investor Update
07.10.12
Ironwood Pharmaceuticals to Host Second Quarter 2012 Investor Update Call
05.29.12
Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences
05.14.12
Ironwood and Forest to Present 17 Linaclotide-Related Abstracts at Digestive Disease Week® 2012
05.14.12
Ironwood and Forest to Present 17 Linaclotide-Related Abstracts at Digestive Disease Week® 2012
05.08.12
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2012 Health Care Conference
05.01.12
Ironwood Pharmaceuticals Provides First Quarter 2012 Investor Update
04.24.12
Ironwood Pharmaceuticals to Host First Quarter 2012 Investor Update Call
04.23.12
Ironwood and Forest Announce FDA Has Extended the Review Period for Linaclotide to September 2012
02.28.12
Ironwood Pharmaceuticals Provides Fourth Quarter 2011 Investor Update
02.27.12
Ironwood Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
02.21.12
Ironwood Pharmaceuticals to Host Fourth Quarter 2011 Investor Update Call
02.13.12
Ironwood Pharmaceuticals Announces Exercise of Over-Allotment Option in Public Offering of Common Stock
02.09.12
Ironwood Pharmaceuticals Prices Public Offering of Common Stock
02.08.12
Ironwood Pharmaceuticals Announces Proposed Public Offering of Common Stock
02.08.12
Ironwood Announces FDA Advisory Committee Meeting Will Not Be Scheduled in Connection with New Drug Application for Linaclotide
01.04.12
Ironwood Pharmaceuticals and Bionomics Announce Collaboration, Research, and License Agreement
01.03.12
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Media contact
Meredith Kaya
617.374.5082
mkaya@ironwoodpharma.com

Latest Tweets